SecBot SecBot
6-K ·Filed Jul 15, 2026

GSK

GSK plc
BULLISH
Impact 7/10
Horizonmonths Processed4mo ago SEC0001654954-26-006663
Notable filing: 6-K
Actionable Insight ▲ Bullish

GSK has completed a transformative $10.6B acquisition, adding near-term FDA decision catalysts. Traders should monitor FDA approval decisions on zidesamtinib and neladalkib later this year, which could drive significant upside. Watch for integration costs and potential guidance updates in GSK's next earnings report.

DirectionBullish
Confidencehigh
Horizonmonths

Drugs in focus

GSK drug pipeline →

Neladalkib

▲ Bullish Named in this 6-K
Impact
Phase
Filed/PDUFA (NDA under FDA Priority Review)
Time to market
If approved, US launch would follow the November 27, 2026 PDUFA date (~3 months away); approval is not guaranteed.
Next catalyst
None dated

What to watchFor GSK shareholders the near-term binary is November 27, 2026: FDA decision on neladalkib (with sibling ROS1 drug zidesamtinib's PDUFA on September 18, 2026 as a read-through). Note the direct equity upside of this drug was already captured, Nuvalent (NUVL) shareholders were cashed out at $124.00/share on July 15, 2026, so any remaining exposure is through mega-cap GSK, where one oncology NDA moves the stock by low single-digit percentages. Watch for FDA advisory-committee activity and any confirmatory-trial requirements before the PDUFA.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$51.45
T+0 close · Jul 15, 2026 · via day close
Latest settled
−9.54%
T+60 · $46.54
Vs SPY
−12.08%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 15 $51.45entry
  2. T+1 · 4mo ago +2.57%α +3.11% · $52.77
  3. T+5 · 4mo ago −1.34%α −0.36% · $50.76
  4. T+20 · 3mo ago −2.24%α −4.58% · $50.30
  5. T+60 · 6w ago −9.54%α −12.08% · $46.54
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GSK completed its $10.6B acquisition of Nuvalent, adding three lung cancer assets (zidesamtinib, neladalkib, NVL-330) with near-term FDA review decisions. The deal is a major strategic expansion into NSCLC, with multi-blockbuster potential if approved.

Key Facts

  • GSK completed acquisition of Nuvalent for aggregate equity value of approximately $10.6 billion (£8.0 billion); net of cash acquired, GSK's aggregate investment is approximately $9.4 billion (£7.1 billion).
  • Acquisition adds three lung cancer assets: zidesamtinib (NVL-520), neladalkib (NVL-655), and NVL-330 (phase I).
  • Zidesamtinib and neladalkib are under FDA review for ROS1-positive and ALK-altered NSCLC with target decision dates later this year; both have Breakthrough Therapy and Orphan Drug Designations.
  • If approved, assets are expected to launch in 2026 with multi-blockbuster potential.
  • GSK CEO Luke Miels highlighted the deal accelerates entry into lung cancer and complements existing pipeline including Ris-Rez (B7-H3 ADC) in phase III.

Financial Impact

Aggregate equity value $10.6B; net cash invested $9.4B, representing ~10% of GSK's market cap.

pipeliner&drevenue

Risk Factors

  • FDA approval risk for zidesamtinib and neladalkib; any adverse regulatory decisions would impair deal value.
  • Integration challenges and potential financing dilution if debt or equity issued.
  • Competitive landscape in NSCLC targeted therapies (ROS1, ALK, HER2) may limit peak sales.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
43% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-006663
Document: 0001654954-26-006663-index-headers.html0001654954-26-006663
Document: 0001654954-26-006663-index.html0001654954-26-006663
Document: 0001654954-26-006663.txt0001654954-26-006663

US Market Status

Market Closed · Opens Wed (10h 13m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 15, 2026